"NF-E2-Related Factor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic-leucine zipper transcription factor that was originally described as a transcriptional regulator controlling expression of the BETA-GLOBIN gene. It may regulate the expression of a wide variety of genes that play a role in protecting cells from oxidative damage.
Descriptor ID |
D051267
|
MeSH Number(s) |
D12.776.260.108.737 D12.776.930.127.737
|
Concept/Terms |
NF-E2-Related Factor 2- NF-E2-Related Factor 2
- NF E2 Related Factor 2
- Nuclear Factor E2-Related Factor 2
- Nuclear Factor E2 Related Factor 2
- Nfe2l2 Protein
- Nuclear Factor (Erythroid-Derived 2)-Like 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "NF-E2-Related Factor 2".
Below are MeSH descriptors whose meaning is more specific than "NF-E2-Related Factor 2".
This graph shows the total number of publications written about "NF-E2-Related Factor 2" by people in this website by year, and whether "NF-E2-Related Factor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2005 | 0 | 3 | 3 |
2006 | 4 | 1 | 5 |
2007 | 8 | 1 | 9 |
2008 | 9 | 0 | 9 |
2009 | 7 | 3 | 10 |
2010 | 3 | 2 | 5 |
2011 | 4 | 3 | 7 |
2012 | 3 | 3 | 6 |
2013 | 5 | 3 | 8 |
2014 | 2 | 1 | 3 |
2015 | 9 | 2 | 11 |
2016 | 4 | 1 | 5 |
2017 | 0 | 4 | 4 |
2018 | 4 | 2 | 6 |
2019 | 6 | 5 | 11 |
2020 | 6 | 5 | 11 |
2021 | 3 | 3 | 6 |
2022 | 1 | 8 | 9 |
2023 | 1 | 10 | 11 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NF-E2-Related Factor 2" by people in Profiles.
-
Genome-wide p63-Target Gene Analyses Reveal TAp63/NRF2-Dependent Oxidative Stress Responses. Cancer Res Commun. 2024 02 01; 4(2):264-278.
-
Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 01; 138(3):664-675.
-
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res. 2023 12 01; 29(23):4958-4972.
-
Restoring glomerular filtration rate by sulforaphane modulates ERK1/2/JNK/p38MAPK, IRF3/iNOS, Nrf2/HO-1 signaling pathways against folic acid-induced acute renal injury in rats. Int Immunopharmacol. 2023 Oct; 123:110777.
-
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer. 2023 10; 184:107293.
-
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
-
An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circ Res. 2023 06 23; 133(1):25-44.
-
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 07; 34(7):589-604.
-
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023 06 20; 41(18):3311-3317.
-
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.